The Korean government, recognizing persistent challenges in the pharmaceutical and bio venture sector, has introduced a new policy framework to address long-standing funding and growth gaps. The Ministry of Health and Welfare and the Ministry of SMEs and Startups jointly announced the ‘4UP strategy’ on March 24, 2024, at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. The policy aims to support the entire cycle of new drug development, from research to global market entry, and to build a robust growth ladder for the K-bio industry. This initiative responds to the sector’s need for continuous support, especially in clinical development and commercialization stages.
The policy directly impacts pharmaceutical and bio ventures, research institutions, and investors in Korea. Through the 4UP strategy—comprising Scale-Up, Speed-Up, Level-Up, and Synergy-Up—the government will provide integrated R&D and commercialization funding, infrastructure access, and regulatory improvements. Notably, promising companies will benefit from the Scale-Up TIPS platform, which packages R&D and business funding, and from enhanced collaboration opportunities with global firms. The strategy also includes support for AI-driven joint R&D and programs to facilitate technology transfer and overseas expansion.
Implementation began with the March 24 policy announcement and will proceed through coordinated actions between the two ministries. Key changes include the introduction of a relay-type support system linking R&D and commercialization funds, pilot integration of research infrastructure in major hubs like Incheon and Osong, and the establishment of specialized statistics and monitoring systems. The government will also revise certification criteria for innovative pharmaceutical companies and foster open innovation through expanded domestic and international partnerships. These measures are designed to create a virtuous cycle connecting investment, R&D, commercialization, and global market success.
Frequently asked questions include: What is the main goal of the 4UP strategy? The goal is to bridge support gaps and accelerate the creation of blockbuster drugs by integrating government and private sector resources. How will companies benefit from the new policy? Selected ventures will receive prioritized funding, infrastructure access, and support for global market entry. What are the expected outcomes? The government anticipates a stronger K-bio ecosystem, increased exports, and enhanced global competitiveness for Korean pharmaceutical and bio ventures.
The 4UP strategy marks a comprehensive and targeted response to the persistent challenges in Korea’s pharmaceutical and bio venture sector. By integrating funding, infrastructure, and regulatory improvements, the government is creating a supportive environment for innovation and commercialization. The focus on AI-driven R&D and open innovation is particularly timely, given global trends in drug development. If effectively implemented, this policy could significantly enhance Korea’s competitiveness in the global pharmaceutical market and drive sustainable growth in the bio industry.